Two new simple and selective assay methods have been presented for the analysis of Escitalopram Oxalate (ESC) and L-Methylfolate (L-MF) in pharmaceutical formulations. The ultraviolet (UV)-Spectrophotometric simultaneous equation method was based on the measurement of absorbance at 238 nm (ʎ max of ESC) and 284 nm (ʎ max of L-MF) in methanol. The assay was linear over the concentration ranges 0.5-12.0 μg/mL for ESC and 0.5-9.0 μg/mL for L-MF. The quantitation limits for ESC and L-MF were found to be 0.912 and 0.667 μg/mL; while the detection limits were 0.301 and 0.220 μg/mL for ESC and L-MF, respectively. The second method involved isocratic reversed-phase liquid chromatography using a mobile phase composed of methanol-0.02 M phosphate buffer (pH 5.5) (75:25, v/v), Hypersil BDS-C 18 Column (5 µm, 250 mm × 4.6 mm i.d.) with detection at 270 nm. The linearity ranges were found to be 3.0-30.0 and 0.75-22.5 μg/mL for ESC and L-MF, respectively. The limits of detection were found to be 1.065 and 1.160 μg/mL for ESC and L-MF, respectively. The limits of quantitation were found to be 3.226 and 3.515 μg/mL for ESC and L-MF, respectively. The proposed methods were successfully applied to the determination of commercially available tablets with a high percentage of recovery, good accuracy and precision.
Introduction

Escitalopram Oxalate (ESC) is chemically [(s)-1-[3-(dimethlyamino)
propyl]-1-(4-flurophenyl)-1,3-dihydro isobenzofuran-5-carbonitrile oxalate] (1) (Fig. S1A ). ESC is a selective serotonin reuptake inhibitor. It is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative of citalopram (2) . The antidepressant action of ESC, the S-enantiomer of racemic citalopram, is presumed to be linked to the potential of serotonergic activity in the central nervous system neuronal reuptake of serotonin (5HT) (2, 3) . ESC is at least 100-fold more potent than the R-enantiomer with respect to its inhibition of the 5HT reuptake and neuronal firing rate. It is mainly used as an antidepressant agent.
Three analytical platforms have been reported for the determination of ESC in pharmaceutical preparations: ultraviolet (UV)-Spectrophotometric (4-9) and reverse phase-high-performance liquid chromatography (RP-HPLC) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and high-performance thin layer chromatography (20) (21) (22) .
L-Methylfolate (L-MF) is chemically (2 S)-2-[[4-[(2-Amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl) methylamino]benzoyl]amino]pentanedioic acid. (Fig. S1B ) L-MF is the primary biologically active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. In the cell, L-MF is used in the methylation of homocysteine to form methionine and tetrahydrofolate (THF). THF is the immediate acceptor of one carbon units for the synthesis of thymidine-DNA, purines (RNA and DNA) and methionine. The un-methylated form, folic acid (vitamin B 9 ), is a synthetic form of folate, and must undergo enzymatic reduction by methylenetetrahydrofolate reductase to become biologically active (23) . L-MF has been proposed for treatment of cardiovascular disease (24, 25) and advanced cancers such as breast colorectal cancers. L-MF is also used in people major depressive disorder who have folate deficiency, or in people with schizophrenia who have hyperhomocysteinemia related to folate deficiency. L-MF is not an antidepressant or anti-psychotic medication. However, L-MF may enhance the effects of antidepressant medications (26) . RP-HPLC methods have been reported for the determination of Folate in food products (27, 28) .
In our literature survey, at present no RP-HPLC and UVSpectrophotometric methods are reported for the simultaneous estimation of ESC and L-MF in tablet formulation. RP-HPLC is a more commonly used method in quality control laboratories because of its high sensitivity and precision. The UV-Spectrophotometric method is also very simple and does not require any reagent, pH adjustment or extraction procedure as well as most reliable for small-scale laboratory premises. Besides, it is necessary to separate and quantify both molecules accurately due to its independent therapeutic use, which is required for psychiatric patient with folic acid deficiency. For this purpose, it was thought worthwhile to develop simple, precise, accurate UVSpectrophotometric (simultaneous equation method) and RP-HPLC methods for simultaneous determination of ESC and L-MF in tablets.
Experimental
Apparatus
Spectrophotometric measurements were performed by using a double beam UV-visible Spectrophotometer (SHIMADZU, Japan Model: 1800) having a pair of 10 mm matched quartz cuvettes, used to measure absorbance of the resulting solutions.
The RP-HPLC analysis was performed on Shimadzu RP-HPLC (SPD-20AT) system equipped with pump (LC-20AT), system controller (SCL-20AT), Injector (Rheodyne injector, 20 µL Capacity), UV/Vis detector (SPD-20AT) and Spinchrom software. Chromatographic separation was achieved isocratically at a temperature of 25°C on Hypersil BDS-C 18 Column (5 µm, 250 mm × 4.6 mm i.d.; KYA TECH Corporation, Japan). The mobile phase was composed of methanol-0.02 M phosphate buffer (pH 5.5; 75:25, v/v) with a flow rate of 1.0 mL/min and UV detection at 270 nm.
Reagents and solutions
ESC and L-MF pure powder was procured as gratis sample from Sunrise Pharma Pvt Ltd (Satej, Gujarat, India); Tablet formulation, Escitafol (Intas Pharmaceuticals Ltd, India), was obtained commercially with the labeled amounts of 10 mg of ESC and 7.5 mg of L-MF. All chemicals and reagents were of analytical-reagent grade.
General procedure
Simultaneous equation UV-Spectrophotometric method Different aliquots of stock solution were transferred to 10-mL volumetric flasks to prepare a final concentration range of 0.5-12.0 µg/ mL for ESC and 0.5-9.0 µg/mL for L-MF, and the volume was diluted to final volume with methanol. The spectra of these standard solutions were scanned against methanol as a blank between 200 and 400 nm. The values of absorbance at 238 and 284 nm were measured for the determination of ESC and L-MF, respectively. The concentrations of each compound versus their absorbance were plotted to establish calibration graphs.
RP-HPLC method
Standard solutions of ESC and L-MF were prepared by dilution of the stock solutions with methanol-phosphate buffer (pH: 5.5) (75:25, v/v). The final concentrations of each drug were between 3.0-30.0 and 0.75-22.5 µg/mL for ESC and L-MF, respectively. The chromatograms were evaluated on the basis of the peak areas.
Assay procedure for tablets
Twenty tablets were accurately weighed and powdered to a fine powder. A quantity of powder equivalent to 100 mg ESC and 75 mg L-MF was weighed and transferred into two different 100 mL volumetric flasks. The volume was diluted with methanol for UV method and mobile phase for RP-HPLC method. Both were sonicated for 30 min and final volume was made up to the mark with respective diluents. The solution was filtered through Whatman filter paper no. 41. Then, 0.8 mL of stock solution was pipette out and transferred to 100 mL volumetric flask and made volume up to mark with methanol to get final solution of ESC (8 μg/mL) and L-MF (6 μg/mL) for UV method; whereas 2 mL of the solution was diluted to 100 mL with mobile phase to get final solution with ESC (20 μg/mL) and L-MF (15 μg/mL) for RP-HPLC method. Appropriate aliquots were subjected to above methods and the amount of ESC and L-MF was determined. Chromatogram of sample solution for RP-HPLC method was obtained.
Method Development and Validation
Method development
Simultaneous equation UV-Spectrophotometric method For UV method, standard stock solutions of 1,000 µg/mL of ESC and 750 µg/mL of L-MF were prepared by dissolving standards 100 mg ESC and 75 mg L-MF in 100 mL of methanol. From these stock solutions, working standard solutions having concentration 10.0 µg/mL of ESC and 7.5 µg/mL of L-MF were prepared by appropriate dilutions. They were scanned in the wavelength range of 400-200 nm and the overlain spectrum was obtained. Two wavelengths 238 nm (λ max of ESC) and 284.0 nm (λ max of L-MF) were selected for the formation of simultaneous equation. The absorptivity coefficients of each drug at both wavelengths were determined. The concentration of two drugs in the mixture was calculated using the following equations:
where A 1 and A 2 are absorbance of mixture at 238 and 284 nm; ax 1 and ax 2 are absorptivities of ESC at 238 and 284 nm, respectively; ay 1 and ay 2 are absorptivities of L-MF at 238 and 284 nm, respectively. C ESC and C L-MF are concentration of ESC and L-MF in mixture. The absorptivities reported are the mean of six independent determinations.
RP-HPLC method
Based on sample solubility and pKa value, various mobile phase compositions were tried to get a good separation. The standard solution containing mixture of ESC and L-MF and as well as individual drugs was run in different mobile phases in order to find the best conditions for separating both the drugs simultaneously. The optimal composition of mobile phase was determined to be methanol:Phosphate buffer (pH 5. 
Method validation
The developed methods of analysis were validated as per the ICH (29) for the parameters like system suitability, specificity, linearity, precision, accuracy, robustness, limit of detection (LOD) and limit of quantitation (LOQ).
System suitability System suitability test is an integral part of chromatographic method, which was used to verify reproducibility of the chromatographic system. To ascertain its effectiveness, certain system suitability test parameters were checked by repetitively injecting the drug solution at the concentration level 20 μg/mL for ESC and 15 μg/mL for L-MF. First of all, the HPLC system was stabilized for 40 min. One blank followed by six replicates of a single calibration standard mixture solution of ESC and L-MF was injected to check the system suitability.
Linearity range
The linearity of proposed methods was evaluated by linear regression analysis, which was calculated by least square method. For UV method, calibration curve was plotted over a concentration range 0.5-12.0 μg/mL for ESC and 0.5-9.0 μg/mL for L-MF. For RP-HPLC method, calibration curve was plotted over a concentration range 3.0-30.0 μg/mL for ESC and 0.75-22.5 μg/mL for L-MF. Method of least square analysis was carried out for getting the slope, intercept and correlation coefficient.
LOD and LOQ
LOD is the lowest concentration in a sample that can be detected, but not necessarily quantified under the stated experimental conditions. The LOQ is the lowest concentration of analyte in a sample that can be determined with acceptable precision and accuracy. The LOD and LOQ were calculated using one of the three methods (Based on Standard Deviation of the Response and the Slope Method) as per ICH guidelines. LOD = 3.3 SD/S LOQ = 10 SD/S where SD is standard deviation of the peak area (n = 5) and S is the slope of the corresponding calibration curve.
Precision
Intraday and interday precision study of ESC and L-MF was carried out by estimating corresponding responses three times on the same day and on three different days for the concentration of 8 μg/mL of ESC and 6 μg/mL of L-MF for UV method and 20 μg/mL of ESC and 15 μg/mL of L-MF for RP-HPLC method. Every sample was injected six times.
Recovery
The accuracy of the method was determined by calculating recoveries of ESC and L-MF by the standard addition method. For UV method, the previously analyzed samples (4.0 μg for ESC and 3.0 μg for L-MF) were spiked with extra concentration levels of 2.0, 4.0 and 6.0 μg for ESC and 1.5, 3.0 and 4.5 μg for L-MF. The total amount drug C ESC and C L-MF was calculated.
For RP-HPLC method, the previously analyzed samples (10 μg for ESC and 7.5 μg for L-MF) were spiked with extra concentration levels of 8, 10 and 12 μg for ESC and 6, 7.5 and 9 μg for L-MF and the mixtures were reanalyzed by the developed method. The recovery studies were carried out in the tablet in triplicates each level.
Robustness
The robustness of the RP-HPLC method was evaluated by changing in flow rate of mobile phase (±20%) to 0.8 and 1.2 mL/min, change in mobile phase ratio (2% absolute) as methanol:phosphate buffer (73:27) and methanol:phosphate buffer (77:23) and change in pH (±0.2 absolute) to 5.3 and 5.7.
Stability
Solution stability is the stability of sample and standard in solution form for specified period of time (24 h at room temperature). Standard and sample preparation was prepared as per test procedure and assay of standard and sample was determined as per methods. Assay of standard and sample solution after 12 and 24 h was determined using freshly prepared standard. The assay obtained was compared with the initial assay value and absolute difference in % assay from initial value was recorded. Under all conditions tested, ESC and L-MF were found to be stable.
Applications of the methods
The applicability of the proposed methods was tested by the determination of drugs in their pharmaceutical preparations. The results of the RP-HPLC method were statistically compared with those obtained by the simultaneous equation UV-Spectrophotometric method. The Student's t-test and variance ratio F-test revealed no significant difference in terms of averages and SDs.
Results and Discussion
For UV method, working standard solutions having concentration 10.0 µg/mL of ESC and 7.5 µg/mL of L-MF were prepared and scanned in the wavelength range of 400-200 nm and the overlain spectrum was obtained (Fig. S2) . Two wavelengths 238 nm (λ max of ESC) and 284.0 nm (λ max of L-MF) were selected for the formation of simultaneous equation. The absorptivities of each drug at both wavelengths were determined. The values of absorptivities of ESC and L-MF at 238 and 284 nm are ax 1 (14,800.75), ax 2 (2,514.10), ay 1 (13,253.80) and ay 2 (29,158.37), respectively. The absorptivities reported are the mean of six independent determinations. The concentrations of two drugs in the sample were calculated using simultaneous equations.
For RP-HPLC method, the mobile phase consisting of methanol-0.02 M phosphate buffer (pH 5.5; 75:25, v/v) at 1 mL/min flow rate was optimized which gave sharp peak, minimum tailing factor with short run time for ESC and L-MF. Retention times of the drugs obtained under these conditions were 3.37 and 5.75 min for ESC and L-MF, respectively.
For quantitative analytical purposes, the wavelength was set at 270 nm as the optimum wavelength throughout the experiment for ESC and L-MF. System suitability parameters are shown in Table I . All the system suitability parameters were evaluated with the back ground of regulatory requirements, which also suggests good chromatographic condition. Chromatogram for standard mixture and sample was obtained (Figs S3 and S4) .
For UV method, calibration curves were plotted over a concentration range 0.5-12.0 μg/mL for ESC and 0.5-9.0 μg/mL for L-MF ( Figs  S5 and S6 was an excellent correlation between absorbance and analyte concentration as well as peak area and analyte concentration (Table II) . The LOD and LOQ were calculated based on the SD of the response and the slope (S) of the calibration curve at levels approximating the LOD and LOQ. For UV-Spectrophotometric method, the LOD and LOQ were found to be 0.301 and 0.912 µg/mL for ESC and 0.220 and 0.667 µg/mL for L-MF, respectively. For the RP-HPLC method, the LOD and LOQ were found to be 1.065 and 3.226 µg/mL for ESC and 1.160 and 3.515 µg/mL for L-MF, respectively, which show that these methods are very sensitive. The results of some analytical parameters (linearity, LOD and LOQ) of the proposed methods are given in Table II .
Precision was studied to find out intraday and interday variations in the test methods of ESC and L-MF for the six times at different intervals on the same day and different days. For UV method, %RSD for intraday precision obtained was 0.27 for ESC and 0.66 for L-MF; and interday precision obtained was 0.54 for ESC and 0.98 for L-MF. On the other side for RP-HPLC method, %RSD for intraday precision was 0.17 for ESC and 0.56 for L-MF and interday precision was 0.20 for ESC and 0.52 for L-MF. The values of % RSD (<2.0%) indicate that the proposed methods are quite precise and reproducible and results are shown in Table III . Recovery studies of the drug were carried out for the accuracy parameter by standard addition method at three different concentrations levels, i.e., multiple level recovery studies. A known amount of ESC and L-MF standards were added into pre-analyzed sample and subjected them to the proposed UV and HPLC method. The % recovery was found to be within the limits as listed in Table IV. Generally, the mean percentage recovery of ESC and L-MF at each level was not less than 98% and not more than 102%. In UV method, percentage recovery of ESC and L-MF was found to be in the range of 98.22-100.14% and 99.04-100.71%. In RP-HPLC method, percentage recovery of ESC and L-MF was found to be in the range of 99.22-100.51% and 99.82-100.54%. The method precision was done and the low % RSD (<2%) values indicate that the proposed methods were in good agreement with measured values. Robustness was done by small changes in the chromatographic conditions like mobile phase flow rate, mobile phase composition, mobile phase pH, etc. It was observed that there were no marked changes in the chromatograms. Infact, the parameters are within the limit, which indicates that the methods are robust and suitable for routine use. The robustness results are presented in Table V. The developed methods were applied to the assay of ESC and L-MF combined tablet dosage form. The sample chromatogram of ESC and L-MF is shown in Fig. S4 . The experimental results are given in Table VI . The results were very close to labeled value of commercial tablets. The results of the RP-HPLC method were statistically compared with those obtained by the simultaneous 
